Agilent Technologies (A) Projected to Post Earnings on Wednesday

Agilent Technologies (NYSE:A) is projected to announce its Q3 2026 results after the market closes on Wednesday, August 26th. Analysts expect Agilent Technologies to announce earnings of $1.49 per share and revenue of $1.8415 billion for the quarter. Agilent Technologies has set its FY 2026 guidance at 6.000-6.100 EPS and its Q3 2026 guidance at 1.480-1.500 EPS. Individuals can find conference call details on the company’s upcoming Q3 2026 earning report page for the latest details on the call scheduled for Wednesday, August 26, 2026 at 4:30 PM ET.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Wednesday, May 27th. The medical research company reported $1.49 EPS for the quarter, topping the consensus estimate of $1.41 by $0.08. Agilent Technologies had a net margin of 19.55% and a return on equity of 24.33%. The company had revenue of $1.83 billion during the quarter, compared to analysts’ expectations of $1.80 billion. During the same quarter in the previous year, the company earned $1.31 EPS. Agilent Technologies’s revenue was up 10.0% on a year-over-year basis. On average, analysts expect Agilent Technologies to post $6 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Agilent Technologies Trading Up 0.2%

Shares of NYSE A opened at $159.25 on Monday. The company’s 50 day simple moving average is $137.57 and its 200 day simple moving average is $126.17. Agilent Technologies has a fifty-two week low of $108.35 and a fifty-two week high of $160.51. The firm has a market capitalization of $44.98 billion, a P/E ratio of 31.98, a P/E/G ratio of 2.80 and a beta of 1.25. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.10 and a quick ratio of 1.62.

Analysts Set New Price Targets

Several research analysts have recently issued reports on A shares. Bank of America upgraded Agilent Technologies from a “neutral” rating to a “buy” rating and reduced their price target for the stock from $150.00 to $145.00 in a research report on Thursday, May 28th. Barclays upped their price objective on Agilent Technologies from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday, June 24th. Sanford C. Bernstein assumed coverage on Agilent Technologies in a research note on Friday, June 26th. They issued an “outperform” rating and a $155.00 target price on the stock. Robert W. Baird raised their target price on Agilent Technologies from $155.00 to $156.00 and gave the stock an “outperform” rating in a report on Tuesday, May 26th. Finally, Weiss Ratings upgraded Agilent Technologies from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, June 2nd. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $160.24.

Institutional Investors Weigh In On Agilent Technologies

Several large investors have recently modified their holdings of the business. Compound Planning Inc. grew its position in shares of Agilent Technologies by 47.8% in the 4th quarter. Compound Planning Inc. now owns 3,705 shares of the medical research company’s stock valued at $504,000 after purchasing an additional 1,199 shares during the period. Invesco Ltd. boosted its position in Agilent Technologies by 32.0% during the fourth quarter. Invesco Ltd. now owns 2,590,715 shares of the medical research company’s stock valued at $352,519,000 after purchasing an additional 627,804 shares during the last quarter. Corient Private Wealth LLC increased its holdings in Agilent Technologies by 53.7% during the fourth quarter. Corient Private Wealth LLC now owns 284,303 shares of the medical research company’s stock worth $38,685,000 after buying an additional 99,385 shares during the last quarter. Mercer Global Advisors Inc. ADV lifted its stake in Agilent Technologies by 1.9% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 60,542 shares of the medical research company’s stock valued at $8,238,000 after purchasing an additional 1,131 shares during the last quarter. Finally, Vident Advisory LLC increased its holdings in shares of Agilent Technologies by 4.7% during the 4th quarter. Vident Advisory LLC now owns 17,052 shares of the medical research company’s stock worth $2,320,000 after acquiring an additional 765 shares during the last quarter.

Agilent Technologies Company Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.